Axl-targeted cancer imaging with humanized antibody h173

Molecular Imaging and Biology

Volumn 16, Issue 4, 2014, Pages 511-518

  Li, Dan ^a,b   Liu, Shuanglong ^a   Liu, Ren ^c   Park, Ryan ^a   Yu, Haiyang ^c,d   Krasnoperov, Valery ^e   Gill, Parkash S ^c   Li, Zibo ^a   Shan, Hong ^b   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e Vasgene Therapeutics Inc   (United States)

Author keywords

Antibody; Axl receptor; Cancer; Near infrared fluorescence (NIRF) imaging

Indexed keywords

ENZYME ANTIBODY; H 173; H 173 ANTIBODY; HUMAN IMMUNOGLOBULIN; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR AXL; UNCLASSIFIED DRUG; 6-CARBOXYFLUORESCEIN; AXL RECEPTOR TYROSINE KINASE; CARBOCYANINE; CY5.5 CYANINE DYE; FLUORESCEIN DERIVATIVE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; EX VIVO STUDY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MOLECULAR IMAGING; MOLECULAR WEIGHT; NEAR INFRARED SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; ENZYMOLOGY; METABOLISM; MOUSE; NEOPLASMS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARBOCYANINES; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FLUORESCEINS; HUMANS; IMMUNOGLOBULIN G; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SPECTROSCOPY, NEAR-INFRARED; TISSUE DISTRIBUTION;

EID: 84904423023     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-013-0714-z     Document Type: Article

References (34)

1. Liu E, Hjelle B, Bishop JM (1988) Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 85:1952-1956 (Pubitemid 24315802)
2. Janssen JW, Schulz AS, Steenvoorden AC et al (1991) A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6:2113-2120 (Pubitemid 21924053)
3. Stitt TN, Conn G, Gore M et al (1995) The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80:661-670
4. Varnum BC, Young C, Elliott G et al (1995) Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373:623-626
5. Linger RM, Keating AK, Earp HS, Graham DK (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100:35-83 (Pubitemid 351932179)
6. Craven RJ, Xu LH, Weiner TM et al (1995) Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 60:791-797
7. Nemoto T, Ohashi K, Akashi T et al (1997) Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 65:195-203 (Pubitemid 27472525)
8. Tsou AP, Wu KM, Tsen TY et al (1998) Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 50:331-340
9. Ito T, Ito M, Naito S et al (1999) Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid 9:563-567 (Pubitemid 29296118)
10. Meric F, Lee WP, Sahin A et al (2002) Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 8:361-367 (Pubitemid 34193951)
11. Sun W, Fujimoto J, Tamaya T (2004) Coexpression of Gas6/Axl in human ovarian cancers. Oncology 66:450-457 (Pubitemid 39370236)
12. Shieh YS, Lai CY, Kao YR et al (2005) Expression of Axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7:1058-1064
13. Wimmel A, Glitz D, Kraus A et al (2001) Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37:2264-2274 (Pubitemid 33001299)
14. Vajkoczy P, Knyazev P, Kunkel A et al (2006) Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 103:5799-5804
15. Nakano T, Tani M, Ishibashi Y et al (2003) Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis 20:665-674 (Pubitemid 37463904)
16. Liu R, Gong M, Li X et al (2010) Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood 116:297-305
17. Lay JD, Hong CC, Huang JS et al (2007) Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67:3878-3887
18. Zhang Z, Lee JC, Lin L et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852-860
19. Li Y, Ye X, Tan C et al (2009) Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28:3442-3455
20. Holland SJ, Pan A, Franci C et al (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70:1544-1554
21. Li D, Liu S, Liu R et al (2013) Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring. Mol Pharm 10:329-336
22. Li D, Liu S, Liu R et al (2013) EphB4-targeted imaging with antibody h131, h131-F(ab')2 and h131-Fab. Mol Pharm 10:4527-4533
23. 64Cu-labeled hAb47 and hAb131 antibodies. J Nucl Med 54:1094-1100
24. Zhang B, Shan H, Li D et al (2012) Different methods of detaching adherent cells signifi cantly affect the detection of TRAIL receptors. Tumori 98:800-803
25. Verma A, Warner SL, Vankayalapati H et al (2011) Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10:1763-1773
26. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725 (Pubitemid 47327396)
27. Song H, Sgouros G (2011) Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv 8:26-44
28. Cardoso MM, Peca IN, Roque AC (2012) Antibody-conjugated nanoparticles for therapeutic applications. Curr Med Chem 19:3103-3127
29. Madhumathi J, Verma RS (2012) Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 15:300-309
30. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136 (Pubitemid 41486394)
31. Xie J, Chen K, Huang J et al (2010) PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 31:3016-3022
32. Liu S, Li D, Huang CW et al (2012) Efficient construction of PET/fluorescence probe based on sarcophagine cage: an opportunity to integrate diagnosis with treatment. Mol Imaging Biol 14:718-724
33. Hutterer M, Knyazev P, Abate A et al (2008) Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14:130-138 (Pubitemid 351377987)
34. Sensi M, Catani M, Castellano G et al (2011) Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol 131:2448-2457 and Bioengineering